Invited Faculty
  • Ronald Van Vollenhoven
    Amsterdam UMC
    Netherlands
  • Professor Ronald F. van Vollenhoven is Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC and Director of the Amsterdam Rheumatology Center in Amsterdam, the Netherlands.

    He received his MD and PhD degrees from the University of Leiden in The Netherlands. After graduating in 1984 he pursued immunology research at Cornell Medical College in New York, followed by specialty training at the State University of New York at Stony Brook and at Stanford University, leading to American Board of Internal Medicine certification in Internal Medicine and Rheumatology.

    From 1993 to 1998 Dr. Van Vollenhoven held a faculty appointment as Assistant Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, and from 1995 he was the Medical Services Chief and Fellowship Director in that division.

    In 1998 Dr. Van Vollenhoven moved to Stockholm, Sweden, where he worked as a Senior Physician and Chief of the Clinical Trials Unit in the Department of Rheumatology at the Karolinska University Hospital and Associate Professor of Rheumatology; and in 2010, he was appointed as Professor and Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute.

    In January 2016 Ronald van Vollenhoven was appointed as Professor of Rheumatology at the University of Amsterdam and the VU University, and Chair of Rheumatology at both the AMC and VUMC hospitals, which in 2018 merged into the Department of Rheumatology and Clinical Immunology of the new Amsterdam UMC. He is also the Director of the Amsterdam Rheumatology Center and Chair of the Rheumatology Research Council at Reade in Amsterdam, all located in Amsterdam, The Netherlands.

    Dr. Van Vollenhoven’s research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases. With his co-workers, he established the Stockholm registry for biological therapies (the STURE database) for this purpose, which supported research projects relating to clinical efficacy, pharmacology, outcomes and pharmacoeconomics. He has been principal investigator in many clinical trials of novel therapies in rheumatic diseases and has contributed to a number of important investigator-initiated trials including the SWEFOT, ADMIRE, and DOSERA trials. He has published over 400 original papers (H-index: 89), book chapters and reviews, and is associate-editor of Dubois’ Lupus Erythematosus (Elsevier, 2014), editor of the textbook Clinical Therapy Research in the Inflammatory Diseases (World Scientific Press, 2015), author of the monograph Biological Therapy of Rheumatoid Arthritis (Springer, 2015) and co-author, with Prof. Laurent Arnaud, of the Handbook of Systemic Lupus Erythematosus (Springer, 2017). In 2004, Dr. Van Vollenhoven was awarded the Scandinavian Research Foundation Prize for excellence in clinical research in rheumatology, he is an honorary member of several rheumatological societies, and in 2019 he was awarded the Dutch Rheumatology Society’s highest award, the Jan van Breemen medal. He is the Editor-in-Chief of Lupus Science & Medicine, Chair-elect of the EULAR Research Committee, past-chair of the Swedish Rheumatology Society Professors’ Council, co-founder of the CERERRA registries collaboration and the NORD-STAR collaboration for Nordic trials in the rheumatic diseases, and the initiator of the Treat-to-Target-in-SLE and DORIS initiatives. Prof. Van Vollenhoven is married and has two grown-up children. Outside his professional life he is an avid classical pianist.
    Research & Clinical Focus

    SLE

    Biologics

    Trials

    Small molecules

    Strategies

    • Date Time Room Session Title Lecture Title
    May 17 15:00-15:30 Room Room 205A+B [Pre-conference Workshop] T2T: Defining LDA and Remission T2T
    May 18 12:00-12:40 Room Grand Ballroom 103 [Luncheon Symposium 2 - BMS] Impact of Autoantibodies in RA Treatment Outcomes and RA Associated
    Co-morbidities    		 Impact of autoantibodies in RA treatment outcomes and RA associated co-morbidities
    May 19 13:20-13:40 Room Grand Ballroom 101 [Concurrent Session 6] New Treatments Type I interferon targeted therapy